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ABSTRACT 
Medulloblastoma (MDB) is an aggressive tumor of Central Nervous System (CNS). Radiotherapy after radical surgery 
has an important role in treatment of standard and high risk patients and is followed by intensive chemotherapy. To 
explore modifications of protein expression induced by in vivo radiotherapy proteomic analysis was performed on a 
case of Anaplastic MDB. 2D-gel electrophoresis and MALDI-TOF mass spectrometry detected qualitative differences 
of protein expression in Anaplastic MDB at diagnosis and in relapse after radiotherapy. Relevant proteomic data were 
confirmed by western blot and Real-Time PCR analysis, validating the presence of Sthatmin 1 (STMN1), Heat shock 
protein 60 (HSP60), HSP27 and Disulfide Isomerase (ER60) among the six proteins present in both samples. The most 
relevant modification induced by radiotherapy was a drastic reduction of the total number of proteins (60.6%) and the 
appearance of few new proteins. The modifications and the striking simplification of proteins expressed by the tumor 
after radiotherapy may allow to tailor subsequent chemotherapy on a rational basis. A proteomic guided chemotherapy 
may be of great benefit to patients. 
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1. Introduction 
Medulloblastoma (MDB) is an aggressive tumor of cen-
tral nervous system (CNS) located in the cerebellum and 
represents the more frequent and studied malignant tu-
mor of CNS of paediatric age [1]. MDB less frequently 
affects adult patients [2,3]. With modern protocols sur-
vival is high (70-80%) but neuropsychological damages 
on developing brain may be severe. Radiotherapy is one 
of the relevant causes of therapy related brain damage. 
The aim of modern protocols is to grade tumor aggres-
siveness relying on solid prognostic factors. The intensity 
of treatment may be modulated by risk group (low-  
standard-high). Such an approach may limit the use of 
radiotherapy to less favorable groups of patients and pro-
tect infants and young children from radiotherapic dam-
ages [4]. 
Proteomic studies on MDB were mainly limited to cell 
lines DAOY and D283 which shared Ded protein, an 
antiapoptotic principle [5]. Modifications induced in vivo 
by radiotherapy have not been investigated with a pro-
teomic approach. The presented case offered the unique 
opportunity to investigate an Anaplastic MDB at diagno-
sis and at relapse after sole radiotherapy. 
2. Materials and Methods 
2.1 Patient 
The patient, a 26 year old white male, presented with a 
large tumor of the cerebellar vermis (Figure 1(a)) which 
was totally resected (Figure 1(b)). Histological diagnosis 
was Anaplastic MDB, according to WHO 2007 classifi-
cation [1]. The patient underwent radiotherapy, which 
delivered 54 Gray on the whole neuraxis with regression 
of clinical symptoms. Eight months later a local relapse 
developed (Figure 1(c)) and a second neurosurgery was 
performed. 
2.2 Proteomics 
2D-electrophoresis using pH range of 3-10 (Bio-Rad) 
was performed as previously described [6] on snap fro-
zen tissue of the primary tumor to detect a complete pro-
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teomic profile of the sample. Since the majority of pro-
teins were included in the 4-7 pH range, to analyze the 
proteins involved in radiotherapy response, further 
analysis of primary tumor and its relapse was limited to 
such range. More than 450 detectable protein spot were 
found on primary tumor and 270 in the relapse gel with 
the aid of image analysis software PDQuest version 7.2 
(Bio-Rad). As previously described [7], the spots excised 
from 2D-electrophoresis Colloidal Comassie stained gels 
were destained (in 50% ACN and 5 mM NH4CO3), de-
hydrated in 100% ACN and digested overnight with 5 µl 
trypsin solution (0,1 mg/ml trypsin and 5 mM NH4CO3). 
The mass spectrometer used in this work was a 
MALDI-TOF (MALDI micro MX, Waters, MA, USA) 
with a delayed extraction unit. Peptide spectra were ob-
tained in reflection mode in the range 800-3000 Da. Da-
tabase searching was performed using the 25 most in-
tense measured peptide masses against the Swiss-Prot 
database (one missed cleavage with the trypsin enzyme 
selected, oxidation of methionine as potential variable 
modification, peptide tolerance of 100 ppm, taxa human) 
using the free search program MASCOT (http://www. 
matrixscience.com).  
Only protein identifications with significant Mascot 
score (p < 0.05) were taken into consideration. 
2.3 Western Blotting  
The presences of Stathmin 1 (STMN1) was investigated 
by western blot. Protein samples (20 µg) were separated 
in a 10% polyacrylamide gel and transferred to nitrocel-
lulose membrane. STM1 rabbit polyclonal antibody (Cell 
Signaling) was diluited using manufacturer's instruction 
and incubated overnight at 4˚C. After incubation with the 
appropriate secondary antibody, immunoreactive bands 
were detected with an enhanced chemiluminescence 
(EuroClone). The membranes were after stripped and 
reprobed for β-Tubulin (rabbit monoclonal, 9F3; Cell 
Signaling, 1:1000 diluition) as a protein loading control.  
2.4 Real Time PCR 
The presence of Heat Shock Proteins 27 (HSP27), 
HSP60, ER60 in both tumor samples was investigated by 
Real-Time PCR analysis in order to validate proteomic 
findings. Ribosomal protein (S14) was used as reference 
gene to normalize cDNA across samples. Primers were 
designed using Primer 3 with the Beacon Designer Soft-
ware (PREMIER Biosoft International) for: 1) HSP27 
forward GCTGACGGTCAAGACCAAGG-3’ and re-
verse 5’-ATGTAGCCATGCTCGTCCTG-3’; 2) HSP60 
forward 5’-GCTGAAGATGTTGATGGAGA-3’ and 
reverse 5’-TTGTCACCAAACCCTGGAGC-3’; 3) ER60 
forward 5’-TTCCTGTTGCTATCAGAACTG3’ and 
reverse 5’-ACCTCTCCAGAGCCTTCCCA-3’. Real- 
time-PCR was performed with the ABI PRISM 7900 Ht 
Applied BioSystem instrument.  
3. Results and Discussion 
The present case offered the unique opportunity of study 
the original tumor (Figure 1(a)) that underwent radical 
resection (1(b)) and relapse (1(c)) after radiotherapy. 
MRI control scan, two weeks after second surgery, de-
tected dorso-lumbar leptomeningeal seeding. Chemo-
therapy was started with Cisplatinum and Vincristin. 
Despite chemotherapy the patient died few weeks later. 
  To investigated radiotherapy response proteomic 
analysis of primary tumor and relapse was performed. 
Figures 1 (d) and (e) demonstrated that these two tissue 
samples (Anaplastic Medulloblastoma at diagnosis and at 
relapse) presented remarkable different proteomic pat-
terns, with striking difference in the distribution and 
number of proteins or spot intensity. From gel compari-
son sixty-one proteins (Tables 1-3) appeared differen-
tially expressed between primary tumor and its relapse 
after radiotherapy. Among the proteins identified, 37 
(60.6%) proteins were only present in the original tumor 
and lost after radiotherapy (Table 1), and 18 (29.5%) 
were only found in the relapse tumor after radiotherapy 
(Table 2); 6 (9.8%) proteins were actually present in 
both samples (Table 3). Several protein biologically re-
lated to MDB growth and aggressiveness were present 
only in the primary tumor: these included MEIS1, which 
has DNA-binding property and a role in embryogenesis 
and in CNS development [8], Annexin VIII involved in 
regulation of process of apoptosis, some Heat Shock 
Proteins (HSP70 protein 5 and 8) and several enzymes or 
enzyme inhibitors (Peroxiredoxin-2, Alpha-1-antiproteinase, 
alfaenolase, Cyclin dependent kinase 9, GTPase activat-
ing protein, etc). An impressive modification of the pro-
tein repertoire was induced by radiotherapy. Only six 
proteins were expressed in both tumor samples (Table 3). 
From these STM1, HSP60, HSP27 and ER60 were further 
investigated. The presence in both samples of STMN1 was 
confirmed by western blot (Figure 2(a)), while that of 
HSP27, HSP60 and Disulfide Isomerase by Real-Time 
PCR. Figure 2(b) illustrated the ratio between messenger 
RNA levels in Anaplastic MDB and levels in MDB after 
radiotherapy. In agreement to proteomic data, HSP27, 
HSP60 and ER60 proteins were expressed in both tumor 
with the similar levels. These conserved proteins, which 
possibly represented an essential protein asset linking the 
original tumour to the post radiotherapy relapse, were 
considered of biological relevance. STM1, a cytosolic 
phosphoprotein involved in cell proliferation and mobil-
ity, has been reported as a marker of aggressiveness in 
MDB [9]. HSPs originally described as chaperonines 
also play a role in tumor development and progression in 
several tumors [10] with possible modulated influence 
depending on histotype. ER60 showed a role in protein 
folding in Endoplasmic Reticulum and, with its precursor 
ER57, interacts with important signalling targets and III  
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(a)                             (b)                             (c) 
 
 
(d)                                                          (e) 
Figure 1. NMR images of the patient. (a) At diagnosis T1- weighted NMR demonstrating a large vermian mass; (b) After 
radical surgery no residual tumor is detectable; (c) At relapse tumor infiltrates cerebellar hemispheres. Comassie blue 
stained 2D-electrophoresis patterns of Anaplastic MDB. 2D-electrophoresis was performed on immobilized pH 4-7 strips, 
followed by SDS-PAGE on 10%, 7cmx8cm gels. (d) 2D-electrophoresis pattern of primary tumor shows a large number of 
proteins. (e) At relapse tumor 2Delectrophoresis demonstrates an impressive reduction of the protein profile. Proteins vali-
date by other techniques are marked by name. Total spots excised from D and E are reported in details in Table 1 
 
beta Tubulin [11].  
Radiotherapy has a key role in the treatment of MDB 
in children as well as in adult patients [12,13] and almost 
all protocols for high risk patients include radiotherapy 
treatment as a second step, after radical surgery, followed 
by chemotherapy. Tumoral cell death induced by radio-
therapy is obtained by DNA damages but relevant dif-
ferences in radiosensitivity were observed in tumors of 
different histotype and the factors conferring resistance 
to radiotherapy are not completely understood [14]. 
MDB is a radiotherapy sensitive neoplasia but mecha-
nism that modulate cell resistance in vivo are not well 
known. A proteomic approach has been utilized on 
epithelial cancers to correlate protein expression to re-
sponse to radiotherapy [15,16]. These studies on colonic 
or breast cancer did not analyze protein expression modi-
fications on RT treated tumors in vivo. Recently, utiliz-
ing a murine model of MDB and MDB cell lines, tumor 
cell modifications after the exposure to a course of total 
body radiation were investigated [17]. This study re- 
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Table 1. Proteins identified by MALDI-TOF only on the sample of the primary tumor 
Entry Description MW pI Score Peptides *C % 
P38646 75 kDa glucose regulated protein GRP 75 73634 5,7795 5 9 54 
P11021 Heat shock 70 kDa protein 5 72288 4,8748 10 34 51 
Q9P157 Serum albumin 71317 5,92 12 24 102 
P11142 Heat shock cognate 71 kDa protein 71082 5,37 10 23 88 
P11142 Heat shock 70 kDa protein 8 70854 5,1998 12 15 54 
P10809 60 kDa heat shock protein, mitochondrial 61187 5,7 6 18 59 
P17987 protein 1 subunit alpha 60305 5,7127 12 4 56 
P13645 Keratin, type I cytoskeletal 10 59020 5,13 9 20 80 
P05187 phosphatase  placental type precursor 57917 5,8326 7 4 67 
P08670 Vimentin 53619 4,8629 10 14 62 
P61980 nuclear ribonucleoprotein K 50944 5,2203 7 16 57 
Q71U36 Tubulin alpha-1A chain 50788 4,94 6 24 59 
Q13885 Tubulin beta-2A chain 50274 4,78 7 22 70 
Q6GMP2 Alpha-enolase 47481 7,01 14 35 123 
Q86U18 Alpha-1-antitrypsin 46878 5,37 16 43 187 
P01009 Alpha 1 antiproteinase 46707 5,2405 5 11 51 
P07339 Cathepsin D 45037 6,1 8 27 80 
O00470 protein Meis1 42988 5,8502 7 4 41 
P50750 Cyclin dependent kinase 9 42750 8,9866 5 5 65 
P50219 protein HB9 40726 7,4603 6 4 61 
Q9UNZ2 cofactor p47 40548 4,8067 9 14 52 
P62140 Serine/threonine-protein phosphatase PP1-beta subunit 37961 5,84 4 14 47 
P22626 Heterogeneous nuclear ribonucleoproteins A2/B1 37464 8,97 7 24 73 
P13928 A8  Annexin VIII 36855 5,436 7 5 45 
P04406 Glyceraldehyde-3-phosphate dehydrogenase 36201 8,57 10 44 65 
Q15181 Inorganic pyrophosphatase 33095 5,54 7 34 99 
O94760 N(G),N(G)-dimethylarginine dimethylaminohydrolase 1 31444 5,53 10 40 116 
P60174 Triosephosphate isomerase 26938 6,45 13 67 198 
P09936 Ubiquitin carboxyl-terminal hydrolase isozyme L1 25151 5,33 10 51 142 
P43487 GTPase activating protein 23295 5,0228 7 10 44 
Q9UC36 Heat shock protein beta-1 22826 5,98 6 32 82 
P32119 Peroxiredoxin-2 22049 5,66 6 35 94 
P30086 Phosphatidylethanolamine-binding protein 1 21158 7,01 10 55 154 
P23528 Cofilin-1 18719 8,22 6 42 73 
P15531 Tumor metastatic process associated protein 17137 5,7662 7 11 64 
Q549N7 Hemoglobin subunit beta 16102 6,75 9 63 158 
P00441 Superoxide dismutase  Cu Zn 15925 5,6655 8 5 44 
*C: coverage 
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Table 2. Proteins identified by MALDI-TOF only on the post-radiotherapy sample 
Entry Description MW pI Score Peptides *C % 
P16234 CD140a antigen 122591 4,8768 8 12 55 
P22681 ubiquitin protein ligase CBL 99583 6,0773 5 4 47 
Q86VS8 homolog 3  hHK3 83074 4,9314 6 5 55 
P52888 oligopeptidase  Endopeptidase 24 15   MP78 78789 5,6409 8 6 43 
Q96BP3 isomerase domain and WD repeat containing protein 1 73527 6,7214 7 6 41 
P16519 convertase 2 precursor  NEC 2 70520 6,0289 7 5 62 
P35398 receptor ROR alpha 62995 5,9366 7 5 76 
O43278 Hepatocyte growth factor activator inhibitor type 1 58360 5,8478 5 4 70 
Q5VTY9 Melanoma antigen recognized by T cells 2 57274 6,9218 6 5 61 
P04217 precursor  Alpha 1 B glycoprotein 54238 5,4948 8 9 57 
Q92733 protein PRCC  Pap.renal.cell.carc.Trans. Ass.gene protein 52385 4,8268 8 4 40 
Q9UC06 finger protein 70 50769 8,2009 7 6 42 
P31943 nuclear ribonucleoprotein H  hnRNP H 49198 5,8513 9 21 50 
Q5JT82 factor 17  Zinc finger protein 393 42550 6,2813 5 5 68 
Q12829 protein Rab 40B 30936 9,936 5 6 79 
O95865 dimethylaminohydrolase 2 29625 5,5895 8 9 68 
Q04760 Aldoketomutase 20706 5,0781 5 7 61 
P09382 Putative MAPK activating protein MP12 14706 5,1409 9 6 54 
*C: coverage 
 
Table 3. Proteins identified by MALDI-TOF in both tumor samples 
Entry Description MW pI Score Peptides *C %
P10809 Heat shock protein 60 61016 5,5503 9 22 47 
P30101 Disulfide isomerase ER 60 56746 5,9299 9 25 46 
P02647 Apolipoprotein A I 30758 5,4309 8 15 47 
P04792 Heat shock 27 22768 5,9588 9 10 55 
P06727 A IV precursor 45371 5,1129 9 27 60 
P16949 Stathmin 17292 5,76 6 29 76 
*C: coverage 
 
vealed important intracellular signalling modifications in 
tumor cells with activation of PI3K pathway. Experi-
mental data may not be directly compared to the in vivo 
effects of radiotherapy on human patients due to higher 
complexity of histology in human MDB [18,19] and the 
sophisticated approach of patients radiotherapy treatment. 
Modifications of protein expression induced in vivo by 
radiotherapy alone on human MDB are practically un-
known. The case presented was someway unique because 
the relapse occurred after radiotherapy alone without any 
contribution of chemotherapy. The radiotherapy induced 
differential protein expression showed a somewhat new 
scenario with three relevant aspects: 1) a reduced asset of 
proteins in MDB after radiotherapy, 2) the appearance of 
new proteins and 3) few conserved proteins. A better 
understanding of radiotherapy induced changes on MDB 
cells may offer the opportunity of a more rational selec-
tions of drug regimens or suggest innovative approaches  
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Figure 2. (a) Western blot analysis of primary tumor and post radiotherapy (Rt) stained by anti-STM1 and anti-β-Tubulin; 
(b) Real-Time PCR analysis of proteins expressed in both tumor in primary tumor and post radiotherapy. Results are pre-
sent as fold increase in post radiotherapy vs primary tumor control. Data presented were normalized to S14 mRNA expres-
sion and are mean ± SD of three experiments 
 
taking advantage of the reduced protein expression after 
radiotherapy [14]. 
Data presented confirmed the importance of Sthatmin 
as a marker of aggressiveness in Anaplastic MDB as this 
protein was one of the few proteins expressed in both of 
the tumor samples.  
In fact the radiotherapy induced changes of protein 
expression, as evidenced by proteomic analysis, may 
represent an escape strategy of the tumor to survive to 
radiotherapy and a reversal to a more undifferentiated, 
stem cell-like status. On the other hand, the new protein 
expression patterns displayed by radiotherapy treated 
cells may modify cell sensibility to specific cytotoxic 
drugs or suggest innovative treatment strategies as the 
findings on the mouse model shows [17]. The expression 
of CD140a (PDGFRa) may be of particular interest as 
one of the possible target of anti-receptor small mole-
cules of recent development [20].  
4. Conclusions 
Proteomic analysis of post “in vivo” radiotherapy of 
Anaplastic Medulloblastoma disclosed relavant modifi-
cations of protein profile. The reduction of proteins pre-
sent in the relapse after radiotherapy alone was impres-
sive: almost 40% of the total protein repertoire was lost 
and few “new” proteins were detected. The expression of 
CD 140 as a new radiotherapy induced protein could be 
of particular interest as a possible target of anti-receptor 
therapeutic approach. A proteomic guided chemotherapy 
based upon protein depauperation induced by radiother-
apy could take advantage of the limited protein expres-
sion and target these proteins, precluding to the tumor 
any survival alternative. 
A detailed study on a large number of cases may dis-
close new opportunities for combined therapy based on 
solid scientific data of radiotherapy effects and not only 
on long lasting empirical experience. 
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